On Monday, Lexicon Pharmaceuticals Inc (LXRX) stock saw a modest uptick, ending the day at $1.27 which represents no change from the prior close of of $1.27. The stock opened at $1.26 and touched a ...
Lexicon Pharmaceuticals, Inc. - GlobeNewswire - Wed Nov 6, 7:00AM CST THE WOODLANDS, Texas, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its ...
Lexicon Pharmaceuticals (NASDAQ:LXRX) is scheduled to announce Q3 earnings results on Tuesday, November 12th, after market ...
chief executive officer and director of Lexicon Pharmaceuticals. “We look forward to working with the FDA as it completes its review of our NDA, and if approved, making Zynquista available to patients ...
Analysts are estimating that Lexicon Pharmaceuticals will report an earnings per share (EPS) of $-0.16. The announcement from Lexicon Pharmaceuticals is eagerly anticipated, with investors seeking ...
On Friday, Lexicon Pharmaceuticals Inc (LXRX) stock saw a decline, ending the day at $1.27 which represents a decrease of $-0.03 or -2.31% from the prior close of $1.3. The stock opened at $1.3 and ...
In terms of industry tailwinds, Trump could lessen pressure from the Federal Trade Commission on mergers and acquisitions, ...
Independent advisers to the FDA voted against recommending Lexicon Pharmaceuticals‘ add-on treatment to insulin therapy for ...
The FDA rejected sotagliflozin 5 years ago for the same indication but for the broader population of adults with T1D, due to ...
Stocktwits on MSN11d
Lexicon Pharmaceuticals Loses Over A Third Of Its Market Cap Post FDA Vote On Drug: Retail Sentiment SoursShares of Lexicon Pharmaceuticals tanked nearly 33.6% as of 11:30 am ET after the drug company’s sotagliflozin drug candidate received a negative vote by a US Food and Drug Administration (FDA) panel, ...
Committee members said there was uncertainty around sotagliflozin in patients with kidney disease. The FDA is currently reviewing the oral therapy as an adjunct to insulin to help control glycemic ...
An FDA advisory committee voted Thursday that it didn’t believe the benefits of Lexicon's (LXRX) diabetes drug sotagliflozin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback